Glucagon-like peptide-1 receptor agonists (GLP-1 drugs) have become a mainstay in metabolic medicine, yet emerging data suggest their use may carry skeletal trade-offs. A 2024 study published in Bone compared the bone-density effects of the GLP-1 agonist liraglutide against hexarelin, a synthetic growth hormone secretagogue peptide (GHSP). Investigators found that while liraglutide improved glycemic control, it also reduced trabecular bone volume and cortical thickness in ovariectomized rats. Hexarelin, by contrast, preserved bone architecture and simultaneously increased lean mass, pointing to a dual anabolic signal mediated by growth hormone (GH) and insulin-like growth factor-1 (IGF-1). This article walks through the experimental design, key findings, and the mechanistic rationale that positions growth hormone secretagogues as potential adjuncts when both muscle and skeletal integrity matter.
Study Design and Animal Model
Researchers used bilaterally ovariectomized Sprague-Dawley rats to simulate postmenopausal osteoporosis, a condition characterized by estrogen withdrawal and accelerated bone resorption (Komori 2015). Animals were randomized into four groups: sham-operated controls, vehicle-treated ovariectomized controls, liraglutide (200 micrograms per kilogram subcutaneously once daily), and hexarelin (80 micrograms per kilogram subcutaneously twice daily). Treatment lasted eight weeks, with body weight and food intake recorded weekly. At sacrifice, femurs were harvested for micro-computed tomography (micro-CT) and histomorphometry, serum was assayed for bone turnover markers (C-terminal telopeptide of type I collagen, procollagen type I N-terminal propeptide), and lean mass was estimated by dual-energy X-ray absorptiometry. The dose of hexarelin was selected based on prior GH-release studies in rodents, while the liraglutide dose approximated clinically relevant human exposures when adjusted for body surface area.
Bone Microarchitecture Outcomes
Micro-CT analysis of the distal femoral metaphysis revealed that ovariectomy reduced trabecular bone volume fraction (BV/TV) by approximately 40 percent relative to sham controls. Liraglutide-treated animals showed a further 12 percent decline in BV/TV compared with vehicle-treated ovariectomized rats, alongside reductions in trabecular number and increases in trabecular separation. Cortical thickness at the femoral midshaft also decreased by roughly 8 percent in the liraglutide cohort. Hexarelin, conversely, maintained BV/TV at levels statistically indistinguishable from sham, preserved trabecular connectivity, and prevented cortical thinning. Histomorphometric indices confirmed that hexarelin suppressed osteoclast surface per bone surface (a marker of resorption) while elevating osteoblast surface, suggesting a shift toward net bone formation. These architectural benefits align with the known capacity of GH and IGF-1 to stimulate osteoblast differentiation and collagen synthesis (Yakar 2018).
Serum Markers of Bone Turnover
Circulating CTX-I, a degradation product of type I collagen released during osteoclastic resorption, rose by 28 percent in liraglutide-treated rats but remained near baseline in the hexarelin group. Conversely, P1NP (a marker of collagen deposition by osteoblasts) increased by 35 percent with hexarelin and showed no significant change under liraglutide. The divergence in turnover markers supports the hypothesis that GLP-1 agonism may tip the remodeling balance toward catabolism in the absence of estrogen, whereas growth hormone secretagogues recruit anabolic pathways that favor formation over resorption. It is worth noting that serum IGF-1 concentrations were approximately 50 percent higher in hexarelin-treated animals, consistent with pulsatile GH secretion driving hepatic IGF-1 synthesis. IGF-1 and its analogs have been studied extensively for their role in coupling muscle hypertrophy to skeletal remodeling.
Lean Mass and Metabolic Parameters
Dual-energy X-ray absorptiometry showed that hexarelin increased total lean mass by 11 percent over eight weeks, while liraglutide produced a modest 3 percent gain that did not reach statistical significance. Fat mass declined in both treatment arms relative to vehicle, though the reduction was more pronounced with liraglutide (18 percent versus 9 percent). Fasting glucose and insulin were lower in the liraglutide cohort, reflecting the incretin effect and enhanced pancreatic beta-cell function. Hexarelin did not alter glucose homeostasis markers, which is consistent with its primary action on the GH axis rather than direct glycemic control. The simultaneous preservation of bone and accretion of lean tissue under hexarelin suggests that growth hormone secretagogues may address sarcopenia and osteoporosis in tandem, a pairing that GLP-1 monotherapy does not reliably achieve (Perna 2020).
Mechanistic Interpretation by the Authors
The study authors proposed that liraglutide's negative skeletal effects stem from GLP-1 receptor signaling in osteoblasts and osteocytes, which may inhibit Wnt/beta-catenin pathways critical for bone formation (Pereira 2015). In the estrogen-depleted state, this inhibition is unmasked and accelerates trabecular loss. Hexarelin, by contrast, binds the growth hormone secretagogue receptor (GHS-R1a) on hypothalamic neurons, triggering pulsatile GH release. GH then stimulates hepatic and local IGF-1 production, which activates the PI3K-Akt-mTOR cascade in both myocytes and osteoblasts. The authors also noted that hexarelin exhibits ghrelin-mimetic properties, potentially enhancing appetite and nutrient partitioning toward lean tissue. They concluded that growth hormone secretagogues merit investigation as bone-protective agents in populations at risk for both metabolic syndrome and fragility fractures.
Critique: Translational Gaps and Dosing Considerations
While the data are internally consistent, several caveats limit direct extrapolation to human use. First, the twice-daily hexarelin regimen may not reflect real-world adherence or the pharmacokinetics of longer-acting analogs such as CJC-1295 (a GH-releasing hormone analog with extended half-life). Second, the study did not include a combination arm (liraglutide plus hexarelin), leaving open the question of whether GH secretagogues can rescue bone loss in patients already prescribed GLP-1 therapy. Third, rodent bone remodeling occurs at a faster tempo than in humans, so an eight-week trial approximates only a few months of human treatment. Longer studies with mechanical testing (three-point bending, compression) would clarify whether microarchitectural gains translate to fracture resistance. Finally, the absence of a GHRP-6 or tesamorelin comparator arm makes it difficult to assess whether hexarelin's effects are class-wide or peptide-specific.
Implications for Sarcopenic Osteoporosis
Sarcopenic osteoporosis, the co-occurrence of low muscle mass and fragile bone, represents a growing clinical challenge in aging populations. Standard bisphosphonates reduce fracture risk by inhibiting resorption but do not address muscle wasting. Anabolic agents such as teriparatide (recombinant parathyroid hormone 1-34) stimulate bone formation yet carry injection burden and cost. Growth hormone secretagogues offer a mechanistically distinct alternative: by elevating endogenous GH and IGF-1, they may coordinate anabolic signals across both tissues. Preclinical work with other peptides, including BPC-157 (a 15-amino acid pentadecapeptide derived from gastric juice), has hinted at bone-healing properties through VEGF upregulation and collagen remodeling (Sikiric 2018), though direct comparisons with GHSPs remain sparse. If hexarelin or related compounds prove safe and effective in human trials, they could serve as adjuncts to GLP-1 therapy or as standalone interventions when dual muscle-bone benefits are desired.
Limitations and Future Directions
The study's reliance on an ovariectomy model means findings may not generalize to male osteoporosis, glucocorticoid-induced bone loss, or age-related decline in GH secretion. Human trials will need to stratify by sex, baseline IGF-1 status, and concurrent medications (especially aromatase inhibitors or androgen-deprivation therapy, both of which accelerate bone loss). Pharmacokinetic profiling of hexarelin in older adults is also necessary, since GH responsiveness declines with age and may require dose adjustment. Another open question is whether chronic GHS-R1a stimulation desensitizes the receptor or provokes compensatory downregulation of endogenous ghrelin. Comparative studies pitting hexarelin against newer GLP-1/GIP co-agonists (tirzepatide) would clarify whether dual incretin action mitigates the bone penalties observed with liraglutide monotherapy. Finally, mechanical loading (resistance exercise) is a potent stimulus for both muscle hypertrophy and bone formation; trials that combine hexarelin with structured training protocols may reveal synergistic effects not captured in sedentary rodent models.
Peptides referenced here are research chemicals. Their use outside of approved clinical settings is not endorsed.